Oncolytics Biotech Logo
CA6823108759
A2JMW5
ONC.TO

Oncolytics Biotech

Kurser indlæses...

Prognose

Køb
  8
Behold
  2
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Oncolytics: Preclinical efficacy of Pelareorep in combination with a pan‑RAS inhibitor

    Oncolytics reports preclinical data showing that Pelareorep combined with a pan‑RAS inhibitor reduced tumor growth in a RAS‑driven colorectal cancer model during the initial intensive dosing phase. There was no evidence of antagonism between Pelareorep and RAS inhibition, but the additive effect was smaller after switching to weekly Pelareorep dosing. The company plans to evaluate additional dosing schedules and RAS‑driven tumor models. Pelareorep is an intravenous immunotherapy in clinical development and has FDA Fast Track status for several gastrointestinal indications. » Mere på de.investing.com


  • FDA dialogue about approval pathway drives Oncolytics Biotech stock

    Oncolytics Biotech has announced a "Type D" meeting with the FDA for early August to discuss adding a randomized part B to the REO 033 study, intended to support both accelerated and full approvals for pelareorep. Part B would retain the existing study design, increase the number of participants and incorporate a blinded independent central review to generate randomized efficacy data without starting a separate trial. The company reports progress in part A (target: 60 patients): about half of the sites are expected to be activated by the end of July and more than 20 patients have been pre-identified; full site activation is planned by the end of August. Oncolytics expects a first tumor response update from part A by the end of 2026 and, subject to FDA feedback, aims to begin recruitment for part B in the first quarter of 2027. » Mere på de.investing.com


  • Oncolytics schedules FDA Type C meeting on approval pathway for pelareorep in anal cancer

    Oncolytics has set a Type C meeting with the FDA for April 16 to discuss a registration‑relevant, single‑arm study plan for pelareorep plus a checkpoint inhibitor in squamous cell carcinoma of the anus in second‑line and later therapy. The planned study would include around 60–70 patients with objective response rate (ORR) as the primary endpoint; earlier data (GOBLET cohort 4) showed an ORR of ~30% with a median duration of response of 17 months versus real‑world rates of 10–14%. The company has a market capitalization of USD 111.52 million, reported a negative free cash flow of USD 26.48 million over the past twelve months, and is given a weak financial rating by InvestingPro. » Mere på de.investing.com


  • Oncolytics Biotech completes first step in relocating its registered office to British Columbia

    Oncolytics Biotech has completed the first part of its planned relocation and moved its jurisdiction of incorporation from Alberta to British Columbia via a process described as a “continuance.” The common shares, company name and NASDAQ trading symbol remain unchanged; the CUSIP and ISIN will remain the same until the completion of the second phase. Shareholders approved the move on January 15, 2026; the second phase foresees a transfer to Nevada effective March 31, 2026, after which the CUSIP and ISIN will change and outstanding shares will be converted into U.S. par value shares. The company adopted new articles of incorporation in British Columbia that differ in part from its previous founding documents. » Mere på de.investing.com


  • FDA grants Fast-Track for Pelareorep — Oncolytics stock jumps sharply

    The FDA has granted Fast Track status to Oncolytics' Pelareorep for treatment of metastatic colorectal cancer with KRAS mutation and MSS in the second-line setting. Clinical data showed an objective response rate of 33% vs about 10% for standard therapies, as well as significantly better median PFS and OS. Oncolytics plans a controlled study starting in March, with first interim results expected by the end of 2026; the addressable market is estimated at USD 3–5 billion annually. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Oncolytics Biotech en omsætning på 0 € og et nettoresultat på -8,57 mio. €
(EUR) september 2026
YoY
Omsætning 0 -
Bruttofortjeneste -15,01 t -
Nettoresultat -8,57 mio. 35,31 %
EBITDA -8,6 mio. 44,68 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
31,03 mio. €
Antal aktier
100,36 mio.
Højeste/laveste i 52 uger
1,18 € - 0,31 €
Udbytte Nej
Beta
1,24
P/E (PE Ratio)
-1,21
PEG (PEG Ratio)
0,26
K/I (PB Ratio)
-5,79
P/S (PS Ratio)
0,00

Virksomhedsprofil

Oncolytics Biotech Inc., et biofarmaceutisk udviklingsselskab, fokuserer på opdagelse og udvikling af lægemiddelprodukter til behandling af kræft. Dets hovedprodukt er pelareorep, et intravenøst administreret immunterapeutisk middel til behandling af solide tumorer og hæmatologiske maligniteter. Oncolytics Biotech Inc. har en samudviklingsaftale med Merck KGaA og Pfizer Inc. om at samudvikle pelareorep i kombination med paclitaxel og avelumab, et humant anti-PD-L1-antistof til behandling af hormonreceptorpositiv/human epidermal vækstfaktor 2-negativ metastatisk brystkræft; samt PrECOG LLC. Selskabet blev stiftet i 1998 og har hovedkontor i Calgary, Canada.

Navn
Oncolytics Biotech
CEO
Jared Kelly
Hjemsted San Diego, ca
Canada
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
05.10.2001
Medarbejdere 29

Tickersymboler

Børs Symbol
Toronto Stock Exchange
ONC.TO
NASDAQ
ONCY
Frankfurt
ONYN.F
🍪

Parqet  bruger cookies. Læs mere